Milestone Pharmaceuticals Inc.
MISTNASDAQHealthcare● Active
$1.23
+$0.00(+0.00%)
Market Cap$105643332
P/E Ratio—
52W High$3.06
52W Low$1
Milestone Pharmaceuticals Inc. (MIST) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MIST · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.20
Est. $0.06 · -433.3%
Revenue
$0.00B
Est. $0.03B · -99.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
MIST reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.23 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 13, 2026 | $0.06 | -$0.20 | -433.3% | $0.00B | $0.03B | -99.2% |
| ▲ Q1 FY2026 | Mar 20, 2026 | -$0.18 | -$0.16 | +11.1% | $0.00B | $0.04B | -96.0% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.17 | -$0.12 | +29.4% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.18 | -$0.20 | -11.1% | — | — | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.19 | -$0.31 | -63.2% | — | — | — |
| ▼ Q1 FY2025 | Mar 13, 2025 | -$0.15 | -$0.19 | -26.7% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.16 | -$0.14 | +12.5% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.20
EPS Est.
$0.06
EPS Surpr.
-433.3%
Revenue
$0.00B
Q1 FY2026
Mar 20, 2026Beat
EPS Actual
-$0.16
EPS Est.
-$0.18
EPS Surpr.
+11.1%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.17
EPS Surpr.
+29.4%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.20
EPS Est.
-$0.18
EPS Surpr.
-11.1%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$0.31
EPS Est.
-$0.19
EPS Surpr.
-63.2%
Revenue
—
Q1 FY2025
Mar 13, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.15
EPS Surpr.
-26.7%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.14
EPS Est.
-$0.16
EPS Surpr.
+12.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.37 | $-0.23 | $-0.08 | 2 |
| Q3 FY2027 | $-0.36 | $-0.23 | $-0.08 | 1 |
| Q2 FY2027 | $-0.35 | $-0.22 | $-0.08 | 1 |
| Q1 FY2027 | $-0.34 | $-0.21 | $-0.07 | 2 |
| Q4 FY2026 | $-0.35 | $-0.22 | $-0.08 | 2 |
| Q3 FY2026 | $-0.26 | $-0.21 | $-0.18 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -433.3% | $1.90 | $1.72 | -9.47% |
| ▲ Q1 FY2026 | Mar 20, 2026 | +11.1% | $1.70 | $1.36 | -20.00% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +29.4% | $1.91 | $1.93 | +1.05% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -11.1% | $1.55 | $1.66 | +7.10% |
| ▼ Q2 FY2025 | May 14, 2025 | -63.2% | $1.19 | $1.17 | -1.68% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -26.7% | $1.93 | $2.03 | +5.18% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +12.5% | $1.94 | $1.87 | -3.61% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +26.3% | $1.33 | $1.41 | +6.02% |
Q2 FY2026-9.47%
Report Date
May 13, 2026
EPS Beat/Miss
-433.3%
Price Before
$1.90
Price After
$1.72
Q1 FY2026-20.00%
Report Date
Mar 20, 2026
EPS Beat/Miss
+11.1%
Price Before
$1.70
Price After
$1.36
Q4 FY2025+1.05%
Report Date
Nov 12, 2025
EPS Beat/Miss
+29.4%
Price Before
$1.91
Price After
$1.93
Q3 FY2025+7.10%
Report Date
Aug 12, 2025
EPS Beat/Miss
-11.1%
Price Before
$1.55
Price After
$1.66
Q2 FY2025-1.68%
Report Date
May 14, 2025
EPS Beat/Miss
-63.2%
Price Before
$1.19
Price After
$1.17
Q1 FY2025+5.18%
Report Date
Mar 13, 2025
EPS Beat/Miss
-26.7%
Price Before
$1.93
Price After
$2.03
Q4 FY2024-3.61%
Report Date
Nov 12, 2024
EPS Beat/Miss
+12.5%
Price Before
$1.94
Price After
$1.87
Q3 FY2024+6.02%
Report Date
Aug 8, 2024
EPS Beat/Miss
+26.3%
Price Before
$1.33
Price After
$1.41
Avg Beat Reaction-4.13%
Avg Miss Reaction+0.28%
Beat Rate4 / 8 quarters
Largest Move-20.00% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MIST ends December
Milestone Pharmaceuticals Inc. (MIST) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.20 — missing the analyst consensus of $0.06 by -433.3%. The next MIST earnings date is expected around September 1, 2026.
Each quarter, investors track MIST earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MIST revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MIST's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MIST earnings · 5 questionsMilestone Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. MIST typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MIST historically reports after market close (AMC).
MIST earnings datewhen is MIST earningsMIST next earnings datewhen does MIST report earningsMIST earnings calendar
▸ Source: FMP · Milestone Pharmaceuticals Inc. SEC filings · US GAAP · Milestone Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026